News Releases

  • Kerry Visit Highlights Cockrell School’s Leadership in Renewable Energy

    On a recent trip to Texas, Secretary of State John Kerry stopped by The University of Texas at Austin to meet with industry experts, UT Austin researchers and local business leaders about the advancements taking place in renewable energy in the Lone Star State.

  • $2.7 Million Grant Advances Treatment to Regenerate Blood Vessels

    Biomedical engineers in the Cockrell School of Engineering at The University of Texas at Austin have received a three-year, $2.7 million grant from the U.S. Department of Defense (DOD) to advance a promising treatment that could help millions of older Americans and people with diabetes affected by peripheral ischemia, a condition that restricts blood flow to muscles in the lower limbs.

  • Alumnus Ernie Cockrell Honored with UT Austin Presidential Citation

    Ernest H. “Ernie” Cockrell, alumnus and longtime supporter of the Cockrell School of Engineering, was honored with a Presidential Citation by UT Austin President Gregory L. Fenves for his exemplary leadership and continued dedication to the university. Cockrell’s father, Ernest Cockrell Jr., is the namesake of the school.

  • Cockrell School Engineers Collaborate to Improve Breast Reconstruction Process for Patients

    For many of the thousands of women who undergo mastectomies each year due to breast cancer, part of the healing process is breast reconstruction. However, reconstruction can be an arduous process based primarily on the surgeon’s own experience and skill. It can take multiple surgeries to get it right, and patients often face an overwhelming series of decisions with a number of options and conflicting preferences.

  • Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval

    Researchers at The University of Texas at Austin successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA).